{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T06:00:06Z","timestamp":1785218406029,"version":"3.55.0"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hepatitis B surface antigen (HBsAg) loss is the ideal treatment endpoint for chronic hepatitis B (CHB). Pegylated interferon alfa-2b (Peg-IFN\u03b1-2b) is currently the preferred drug for achieving HBsAg loss, but its efficacy varies significantly among different patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This multicenter, retrospective real-world study enrolled CHB patients treated with Peg-IFN\u03b1-2b for \u226548 weeks. Patients were divided into cured and uncured groups based on week-48 HBsAg status and randomly assigned to training and validation cohorts (7:3). Logistic regression identified independent predictors of HBsAg loss and constructed a predictive model. The model\u2019s discriminative ability, calibration, and clinical applicability were evaluated using receiver operating characteristic (ROC) curve analysis, calibration curves, Hosmer\u2013Lemeshow test, and decision analysis curve (DCA) analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 859 patients, 133 (15.5%) achieved HBsAg loss at week 48. Multivariate analysis identified combination therapy with traditional Chinese medicine (TCM) (OR\u00a0=\u00a03.83), lower baseline HBsAg (OR\u00a0=\u00a00.32), lower baseline aspartate aminotransferase (AST) (OR\u00a0=\u00a00.97), and entecavir (ETV) regimen (OR\u00a0=\u00a00.33) as independent predictors. The model demonstrated strong discrimination and calibration performance, with AUCs of 0.884 in the training cohort and 0.866 in the validation cohort. Logit(P)=-0.87-1.12*HBsAg(log10)+1.34*group-0.03*AST-1.1\u00d7ETV. Note: group (1=no combination with TCM, 2=combination with TCM), ETV (0=non-ETV antiviral regimen, 1=ETV antiviral regimen).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The combination of TCM therapy, low baseline HBsAg levels, lower baseline AST levels, and non-ETV antiviral regimens were significant predictors of HBsAg loss at week 48 in CHB patients receiving 48-week Peg-IFN\u03b1-2b treatment. The predictive model we developed demonstrated high accuracy and potential clinical utility.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key points<\/jats:title>\n                    <jats:p>This study focused on the establishment and validation of a clinical prediction model for HBsAg loss based on a large two-center cohort including 859 patients with CHB. The model was constructed using rigorous statistical methods and further evaluated through both internal and external validation. The results demonstrated good discrimination, calibration, and clinical net benefit, suggesting that the model may serve as a practical tool to help clinicians estimate the probability of HBsAg loss and facilitate individualized antiviral treatment strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcimb.2026.1865116","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T05:34:20Z","timestamp":1785216860000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Construction and validation of a predictive model for HBsAg loss in chronic hepatitis B patients treated with Peg-IFN\u03b1-2b"],"prefix":"10.3389","volume":"16","author":[{"given":"Xinrui","family":"Ren","sequence":"first","affiliation":[{"name":"Department of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Sheng","sequence":"additional","affiliation":[{"name":"Department of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengbinkelvin","family":"Wong","sequence":"additional","affiliation":[{"name":"School of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]},{"name":"Laboratory of Cellular Immunity, Shanghai Key Laboratory of Traditional Chinese Clinical Medicine, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Zhongshan Hospital, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Song","sequence":"additional","affiliation":[{"name":"School of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanchun","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]},{"name":"Laboratory of Cellular Immunity, Shanghai Key Laboratory of Traditional Chinese Clinical Medicine, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueqiu","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]},{"name":"Laboratory of Cellular Immunity, Shanghai Key Laboratory of Traditional Chinese Clinical Medicine, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Pudong","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingying","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]},{"name":"School of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S2468-1253(16)30189-3","article-title":"Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: A randomised, controlled, open-label trial","volume":"2","author":"Bourliere","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B2","first-page":"1309","article-title":"Guidelines for the prevention and treatment of chronic hepatitis B (Version 2022)","volume":"30","year":"2022","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"B3","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1001\/jamaoncol.2018.4070","article-title":"Risk of hepatocellular carcinoma in patients treated with entecavir vs tenofovir for chronic hepatitis B","volume":"5","author":"Choi","year":"2019","journal-title":"JAMA Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1007\/s12072-025-10936-x","article-title":"Machine learning prediction of rapid HBsAg seroclearance at week 24 in inactive carriers treated with pegylated interferon","volume":"19","author":"Dong","year":"2025","journal-title":"Hepatol. Int."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v31.i44.112719","article-title":"Retreatment hepatitis B surface antigen clearance prediction model identifies pegylated interferon alpha candidates in chronic hepatitis B","volume":"31","author":"Fu","year":"2025","journal-title":"World J. Gastroenterol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s13020-023-00861-2","article-title":"The role of traditional Chinese medicine in anti-HBV: Background, progress, and challenges","volume":"18","author":"Ge","year":"2023","journal-title":"Chin. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.14218\/JCTH.2017.00072","article-title":"HBsAg loss with peg-interferon alfa-2a in hepatitis B patients with partial response to nucleos(t)ide analog: New switch study","volume":"6","author":"Hu","year":"2018","journal-title":"J. Clin. Trans. Hepatol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1007\/s12072-024-10648-8","article-title":"Predictors of HBsAg seroclearance in patients with chronic HBV infection treated with pegylated interferon-\u03b1: a systematic review and meta-analysis","volume":"18","author":"Jiang","year":"2024","journal-title":"Hepatol. Int."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2025.1734654","article-title":"A machine learning-based predictive model for 48-week hepatitis B surface antigen seroclearance in chronic hepatitis B patients treated with pegylated interferon \u03b1-2b: Prediction at week 24","volume":"13","author":"Kong","year":"2025","journal-title":"Front. Cell Dev. Biol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"143","DOI":"10.14218\/FIM.2025.00020","article-title":"Traditional Chinese medicine combined with peginterferon \u03b1-2b in chronic hepatitis B: A real-world cohort study","volume":"4","author":"Liang","year":"2025","journal-title":"Future Integr. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"37","DOI":"10.20141\/j.0411-9584.2025.11.10","article-title":"Real-world study on the combination of traditional Chinese medicine prescriptions and pegylated interferon \u03b1-2b in the treatment of chronic hepatitis B","volume":"56","author":"Lin","year":"2025","journal-title":"Jiangxi J. Traditional Chin. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/S1473-3099(16)30204-3","article-title":"Requirements for global elimination of hepatitis B: A modelling study","volume":"16","author":"Nayagam","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s12985-021-01589-x","article-title":"Functional cure for chronic hepatitis B: Accessibility durability, and prognosis","volume":"18","author":"Song","year":"2021","journal-title":"Virol. J."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/v17010044","article-title":"Decrease in HBsAg after TAF switching from entecavir during long-term treatment of chronic hepatitis B virus infection","volume":"17","author":"Tajiri","year":"2024","journal-title":"Viruses"},{"key":"B15","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1007\/s12072-024-10764-5","article-title":"Predictive model for HBsAg clearance rate in chronic hepatitis B patients treated with pegylated interferon \u03b1-2b for 48 weeks","volume":"19","author":"Tan","year":"2024","journal-title":"Hepatol. Int."},{"key":"B16","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.jhep.2020.04.013","article-title":"Hepatitis B surface antigen seroclearance: Immune mechanisms, clinical impact, importance for drug development","volume":"73","author":"Tout","year":"2020","journal-title":"J. Hepatol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"702","DOI":"10.15537\/smj.2025.46.6.20241004","article-title":"Evaluation of HBsAg and HBeAg seroconversion rates in patients diagnosed with chronic hepatitis B","volume":"46","author":"Toygar Deniz","year":"2025","journal-title":"Saudi Med. J."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0262764","article-title":"Superiority of tenofovir alafenamide fumarate over entecavir for serum HBsAg level reduction in patients with chronic HBV infection: a 144-week outcome study after switching of the nucleos(t)ide analog","volume":"17","author":"Uchida","year":"2022","journal-title":"PloS One"},{"key":"B19","volume-title":"Effects of Shugan Jianpi Compound Medicinal Serum on JAK2, STAT3 Mrna and Hbsag Expression in Hepg2.2.15 Cells","author":"Wang","year":"2017"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2023.1332232","article-title":"Clinical cure induced by pegylated interferon \u03b1-2b in the advantaged population of chronic hepatitis B virus infection: A retrospective cohort study","volume":"13","author":"Wen","year":"2024","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"B21","first-page":"247","article-title":"Clinical efficacy and influencing factors of pegylated interferon \u03b1-2b combined with nucleos(t)ide analogs in the treatment of chronic hepatitis B patients with low-level hepatitis B virus surface antigen","volume":"16","author":"Xie","year":"2022","journal-title":"Chin. J. Exp. Clin. Infect. Dis."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1528758","article-title":"Exploring using HBsAg to predict interferon treatment course to achieve clinical cure in chronic hepatitis B patients: a clinical study","volume":"15","author":"Yan","year":"2025","journal-title":"Front. Immunol."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.997608","article-title":"Interferon add-on therapy increased clinical cure significantly for interferon-experienced chronic hepatitis B patients with low HBsAg","volume":"13","author":"Yang","year":"2022","journal-title":"Front. Immunol."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.01780-25","article-title":"Predictive value of hepatic, hematological, and immunological markers and their temporal dynamics in chronic hepatitis B functional cure","volume":"13","author":"Zeng","year":"2025","journal-title":"Microbiol. Spectr."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1038\/s41598-024-51292-4","article-title":"Effect of interferon therapy on quality of life in patients with chronic hepatitis B","volume":"14","author":"Zhang","year":"2024","journal-title":"Sci. Rep."},{"key":"B26","doi-asserted-by":"publisher","first-page":"845","DOI":"10.2147\/IDR.S195144","article-title":"Comparison of pegylated interferon monotherapy and de novo pegylated interferon plus tenofovir combination therapy in patients with chronic hepatitis B","volume":"12","author":"Zheng","year":"2019","journal-title":"Infection Drug Resistance"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2025.1615327","article-title":"Determinants of functional cure in interferon-treated chronic hepatitis B: a retrospective cohort analysis of HBsAg dynamics and clinical predictors","volume":"15","author":"Zhou","year":"2025","journal-title":"Front. Cell. Infect. Microbiol."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2026.1865116\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T05:34:21Z","timestamp":1785216861000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2026.1865116\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":27,"alternative-id":["10.3389\/fcimb.2026.1865116"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2026.1865116","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]},"article-number":"1865116"}}